Date:1/23/2013

ensed Consolidated Balance Sheets - GAAP (In millions)(Unaudited)December 31, December 31, 20122011AssetsCurrent assets:Cash, cash equivalents and marketable securities$
24,061$
20,641Trade receivables, net2,5182,896Inventories2,7442,484Other current assets1,8861,572Total current assets31,20927,593Property, plant and equipment, net5,3265,420Intangible assets, net3,9682,584Goodwill12,66211,750Other assets1,1331,524Total assets$
54,298$
48,871Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued liabilities$
5,608$
5,670Current portion of long-term debt2,49584Total current liabilities8,1035,754Long-term debt24,03421,344Other non-current liabilities3,1012,744Stockholders' equity19,06019,029Total liabilities and stockholders' equity$
54,298$
48,871Shares outstanding756796Amgen Inc.GAAP to "Adjusted" Reconciliations(In millions)(Unaudited)Three months endedYears endedDecember 31, December 31, 2012201120122011GAAP cost of sales$
852$
56$   2,918$
2,427Adjustments to cost of sales:Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations (a)(118)(11)(160)(65)Acquisition-related expenses

(4)-(11)(7)Stock option expense (b)(3)(2)(12)(10)Total adjustments to cost of sales(125)(13)(183)(82)Adjusted cost of sales$
727$
43$   2,735$
2,345GAAP research and development expenses$
938$
851$   3,380$
3,167Adjustments to research and development expenses:Acquisition-related expenses

(16)(1)(50)(28)Certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations

--(12)-Reversal of previously accrued expenses for bonuses and stock-based compensation awards, which were forfeited as a result of the employees' termination pursuant to our continuing efforts to improve cost efficiencies in our operations

---12Stock option expense  (b)(5)(8)(22)(35)To
'/>"/>

SOURCE Amgen Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
2. MDHI Receives Term Sheet for Working Capital and Acquisition Financing -- Company Hits Profitability on Recurring Revenues
3. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
4. InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million
5. AMILPAR - Revenues Grow 18% and EBITDA Increases 19% in 1H12
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
8. CitiusTech Announces H1 2012 Results - 65% Growth in Half Year Revenues
9. Herborium Group Reports Record 6 Month Revenues
10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012